Phase II
The new chief executive officer of Versanis is going to push the obesity drug bimagrumab in the limelight against Novo and Lilly’s drug. Here’s all that you need to know.
Avista Therapeutics inked a partnership deal with Swiss pharma giant Roche to develop AAV gene therapy vectors for eye diseases.
Sanofi has terminated a development agreement with Regulus in Alport syndrome, while Merck reaches the point of futility in a Phase III colorectal cancer trial.
Innovent Biologics’ Phase II trial of mazdutide, a potential treatment for type 2 diabetes, showed the drug met its primary endpoint by successfully reducing HbA1c levels.
The buyout comes on the heels of promising Phase I/II results from GTX-102, an antisense oligonucleotide candidate being developed to treat Angelman syndrome.
In what it is calling a strategic decision, Sesen Bio announced Monday that it has paused development activities of Vicineum, its lead asset, in the United States.
MacroGenics’ Phase II trial shuts down after a patient death believed to be related to enoblituzumab combo, while Exelixis’ Cabometyx combo improves PFS in renal cell carcinoma.
As a result of this new data, the company “has improved the statistical analysis of the ALLOB Phase IIb study.” The changes should speed up the overall recruitment and study.
Omega Therapeutics announced Thursday that the Investigational New Drug (IND) application for its hepatocellular carcinoma (HCC) candidate OTX-2002 has been granted by the FDA.
Clene, Inc. released data that shows its add-on treatment, CNM-Au8, significantly improved survival in patients with amyotrophic lateral sclerosis (ALS) by 70%.
PRESS RELEASES